Literature DB >> 18820132

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

Mojgan Ahmadzadeh1, Aloisio Felipe-Silva, Bianca Heemskerk, Daniel J Powell, John R Wunderlich, Maria J Merino, Steven A Rosenberg.   

Abstract

Regulatory T (T(reg)) cells are often found in human tumors; however, their functional characteristics have been difficult to evaluate due to low cell numbers and the inability to adequately distinguish between activated and T(reg) cell populations. Using a novel approach, we examined the intracellular cytokine production capacity of tumor-infiltrating T cells in the single-cell suspensions of enzymatically digested tumors to differentiate T(reg) cells from effector T cells. Similar to T(reg) cells in the peripheral blood of healthy individuals, tumor-infiltrating FOXP3(+)CD4 T cells, unlike FOXP3(-) T cells, were unable to produce IL-2 and IFN-gamma upon ex vivo stimulation, indicating that FOXP3 expression is a valid biological marker for human T(reg) cells even in the tumor microenvironment. Accordingly, we enumerated FOXP3(+)CD4 T(reg) cells in intratumoral and peritumoral sections of metastatic melanoma tumors and found a significant increase in proportion of FOXP3(+)CD4 T(reg) cells in the intratumoral compared with peritumoral areas. Moreover, their frequencies were 3- to 5-fold higher in tumors than in peripheral blood from the same patients or healthy donors, respectively. These findings demonstrate that the tumor-infiltrating CD4 T(reg) cell population is accurately depicted by FOXP3 expression, they selectively accumulate in tumors, and their frequency in peripheral blood does not properly reflect tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820132      PMCID: PMC2954707          DOI: 10.1182/blood-2008-06-163048

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood.

Authors:  S Yamagiwa; J D Gray; S Hashimoto; D A Horwitz
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

2.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

3.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

4.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

5.  Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.

Authors:  Barbara Valzasina; Silvia Piconese; Cristiana Guiducci; Mario P Colombo
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

7.  Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma.

Authors:  Luis Vence; A Karolina Palucka; Joseph W Fay; Tomoki Ito; Yong-Jun Liu; Jacques Banchereau; Hideki Ueno
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

Review 8.  FOXP3: of mice and men.

Authors:  Steven F Ziegler
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Authors:  Udaya K Liyanage; Todd T Moore; Hong-Gu Joo; Yoshiyuki Tanaka; Virginia Herrmann; Gerard Doherty; Jeffrey A Drebin; Steven M Strasberg; Timothy J Eberlein; Peter S Goedegebuure; David C Linehan
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

10.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy.

Authors:  R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

View more
  55 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

2.  Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.

Authors:  Natalia Martin-Orozco; Yufeng Li; Yijun Wang; Shijuan Liu; Patrick Hwu; Yong-Jun Liu; Chen Dong; Laszlo Radvanyi
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

3.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

Review 4.  Skin barrier immunity and ageing.

Authors:  Emma S Chambers; Milica Vukmanovic-Stejic
Journal:  Immunology       Date:  2019-12-04       Impact factor: 7.397

Review 5.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

6.  Role played by CD4+FOXP3+ regulatory T Cells in suppression of host responses to Haemophilus ducreyi during experimental infection of human volunteers.

Authors:  Wei Li; Klara Tenner-Racz; Paul Racz; Diane M Janowicz; Kate R Fortney; Barry P Katz; Stanley M Spinola
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

Review 7.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.

Authors:  Michal Kuczma; Magdalena Kopij; Iwona Pawlikowska; Cong-Yi Wang; Grzegorz A Rempala; Piotr Kraj
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

Review 9.  Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.

Authors:  Emanuela M Iancu; Petra Baumgaertner; Sébastien Wieckowski; Daniel E Speiser; Nathalie Rufer
Journal:  J Biomed Biotechnol       Date:  2010-11-14

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.